Prevention of Thrombus Growth by Antithrombin III-Dependent and Two Direct Thrombin Inhibitors in Rabbits: Implications for Antithrombotic Therapy

Summary

We compared the abilities of heparin and two direct thrombin inhibitors to prevent fibrin accretion onto pre-existing thrombi in rabbits. Inhibition of thrombus growth was measured as the ability of each test compound to inhibit the accretion of ¹²⁵I-fibrin onto thrombi pre-formed in jugular veins of rabbits. When administered as a continuous infusion, the two direct (i. e. antithrombin III-independent) thrombin inhibitors, r-hirudin and a tripeptide, Ac(D)-Phe-Pro-bor-Arg (P-8714) inhibited fibrin accretion as effectively as heparin, but did so in doses which generated little systemic anticoagulation, as compared to the marked anticoagulation associated with the heparin effect. However, both r-hirudin and P-8714 were more effective when they were administered as a single bolus injection than as a continuous infusion. Under the former conditions, there was only a transient systemic anticoagulant effect. We conclude that direct or antithrombin III-independent thrombin inhibitors are more effective than heparin in preventing thrombus growth. The limited effect of heparin is likely due to fibrin impairing the ability of heparin/antithrombin III to inactivate thrombin.

• REFERENCES

• 1 Gallus AS, Hirsh J. Antithrombotic Drugs: Part I. Drugs 1987; 12: 41-68
• 2 Adar R, Salzman EM. Treatment of thrombosis of veins of the lower extremities. N Engl J Med 1972; 292: 348-350
• 3 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986; 89: 26S-35S
• 4 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inhibition by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; : 3619-3623
• 5 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. J Clin Invest 1989; 84: 1096-1104
• 6 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 7 Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 1991; 117: 359-364
• 8 Okwusidi J, Falcone M, Van Ryn-McKenna J, Hirsh J, Ofosu FA, Buchanan MR. In vivo catalysis of thrombin inhibition by antithrombin III or heparin cofactor II and antithrombotic effect: differential effects of unfractionated heparin and dermatan sulphate. Thrombotic Haemorrh Disorders 1990; 1: 77-80
• 9 Regoeczi E. Fibrinogen catabolism: kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 1970; 38: 111-121
• 10 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 1989; 556: 304-312
• 11 Procter RR, Rappaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-218
• 12 Rosner BA. Analysis of variance. In: Fundamentals of Biostatistics. PWS Publishers, Boston, MA. 1982; pp 410-447
• 13 Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW II. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990; 249: 277-280
• 14 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406
• 15 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemostas 1990; 63: 204-207
• 16 Bourdon P, Fenton JW II, Marganore JM. Affinity labeling of lysine-149 in the anion-binding exosite of human α-thrombin with an N^α-(dinitrofluorobenzyl) hirudin C-terminal peptide. Biochemistry. 1990; 29: 6379-6384
• 17 Ofosu FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemostas 1985; 11: 133-137
• 18 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1986; 485: 41-55
• 19 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114